کلمات کلیدی مربوط به کتاب آکادمی ملی بیوشیمی بالینی آزمایشگاه پزشکی آزمایشگاه دستورالعمل عمل: نشانگرهای زیستی در حال ظهور بیماری های قلبی عروقی و سکته مغزی: رشته های پزشکی، قلب و عروق
در صورت تبدیل فایل کتاب National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers of Cardiovascular Disease and Stroke به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب آکادمی ملی بیوشیمی بالینی آزمایشگاه پزشکی آزمایشگاه دستورالعمل عمل: نشانگرهای زیستی در حال ظهور بیماری های قلبی عروقی و سکته مغزی نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
Draft Guidelines to be discussed at the 2006 Beckman
Conference, 12 p.
NACB LMPG Committee Members:
Centers for Disease Control and Prevention, Atlanta,
Georgia
University of Maryland School of Medicine, Baltimore,
Maryland
University of Vermont, Colchester, Vermont
Baylor College of Medicine, Houston, Texas
University of Texas Southwestern Medical Center, Dallas,
Texas
Framingham Heart Study, Framingham, Massachusetts
Children’s Hospital, Boston, Massachusetts
Emory University School of Medicine, Atlanta, Georgia
Болезни сердца и инсульт по-прежнему
являются ведущей причиной смерти в США . В результате ,
исследователи продолжают искать новые и новые биомаркеры риска
возникновения этих заболеваний . Поскольку многие из этих новых
биомаркеров не так хорошо документированы , как в случае
обычных липидов и липопротеиновых факторов риска , их значение
в клинической практике необходимо было оценить и составить
соответствующие руководящие принципы для их предполагаемого
клинического использования.
For more than 20 years, coronary
heart disease and stroke have been the first and third
leading causes of death and major causes of disability in the
United States and other
developed countries. These are estimated to be the first and
second leading causes of
death in the world today and are expected to remain so by the
year
2020. Despite
significant reduction in all standardized mortality from
cardiovascular disease (CVD)
over the past 20 years, CVD remains the number one cause of
death in the United States,
out ranking all cancers by more than 60%. More than 70.1
million Americans have
some form of cardiovascular disease. Public health priorities
for prevention of
cardiovascular events and stroke as addressed in Healthy People
2010 are prevention of
risk, detection and treatment of risk factors, early
identification and treatment of heart
attacks and stroke, and prevention of recurrent cardiovascular
events. Thus the
search for biomarkers that will better detect coronary patients
with disease who could
potentially benefit from intensive primary prevention efforts
is critically important.
The American Heart Association and the National Cholesterol
Education Program’s
(NCEP) Adult Treatment Panel III (ATP III) have each issued
recommendations
designed to identify more people who are asymptomatic and
clinically free of coronary
heart disease, but at sufficiently high risk for a future
coronary event in order to justify
more intensive risk reduction efforts. Within these
recommendations are specific risk
factors, including total cholesterol, LDL and HDL cholesterol,
that are typically used in
risk prediction algorithms, such as the Framingham Risk Score,
to estimate a global risk assessment for CVD. However, these
predictive models based on conventional risk
factors are underutilized and have a lower than desired
accuracy, thus providing a
stimulus to search for new tools to refine CVD risk prediction.
In recent years the
number of new candidate risk factors that have been proposed as
significant predictors of
cardiovascular disease and its complications has grown
considerably. These
biomarkers are termed emerging risk factors because they are
associated with an
increased risk for CVD, but their causative, independent, and
quantitative contributions to
CVD are not as well documented as those of dyslipdemia, high
blood pressure, and
smoking – the major, longest established risk factors.